A Study of Econazole Foam 1% in Athlete's Foot - Full Text View

Sponsored by:	Quinnova Pharmaceuticals, Inc.
Information provided by:	Quinnova Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:	NCT00768599

Purpose

This is a 6-week clinical study (4 weeks of treatment, once per day, plus a 2-week follow-up period) of a topical foam to treat athlete's foot. The active ingredient in the foam -- econazole nitrate 1% -- is the same active pharmaceutical ingredient in a cream that your doctor can currently prescribe to treat athlete's foot. This study will help to understand if the foam works the same as the cream to treat athlete's foot.

Condition	Intervention	Phase
Tinea Pedis Athlete's Foot	Drug: Econazole Nitrate Cream 1% Drug: Econazole Nitrate Foam 1% Drug: Vehicle Foam	Phase II

MedlinePlus related topics: Athlete's Foot Foot Health Tinea Infections

Drug Information available for: Econazole Econazole nitrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis

Further study details as provided by Quinnova Pharmaceuticals, Inc.:

Primary Outcome Measures:

Complete Cure: defined as a negative KOH and negative culture and no evidence of clinical disease as indicated by scores of 0 for each sign and symptom at Day 43. [ Time Frame: Day 43 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Effective Treatment: defined as a negative KOH, negative culture, no or mild erythema and/or scaling/hyperkeratosis (score of 0 or 1) with all other signs and symptoms being absent (score = 0) at Day 43. [ Time Frame: Day 29 and 43 ] [ Designated as safety issue: No ]

Enrollment:	135
Study Start Date:	March 2008
Study Completion Date:	October 2008
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator Econazole Nitrate Cream 1%	Drug: Econazole Nitrate Cream 1% Topical cream, applied once daily for 4 weeks.
2: Experimental Econazole Nitrate Foam 1%	Drug: Econazole Nitrate Foam 1% Topical foam, applied once daily for 4 weeks.
3: Placebo Comparator Vehicle Foam	Drug: Vehicle Foam Topical foam, applied once daily for 4 weeks.

Detailed Description:

Treating athlete's foot with a cream can leave a greasy, wet feeling on the foot that is uncomfortable to the user and messy on clothing and foot wear. A foam formulation that spreads easily and rubs-in easily that is as effective as the (reference) cream formulation in treating athlete's foot would be a benefit to the user. This study is designed to substantiate a clinical bridge between econazole nitrate foam 1% and econazole nitrate cream 1% based on clinical outcome, safety, and pharmacokinetic data. The study is (foam) vehicle-controlled and is randomized 1 to 1 to 1 (foam:cream:vehicle).

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Be at least 18 years or age and of either sex.
Has a clinical diagnosis of tinea pedis with at least i) moderate scaling(interdigital and/or moccasin) and ii) mild erythema (interdigital only).
Be willing to give informed consent.
Be willing and able to give informed consent.
Has microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte at Baseline. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture.
Be in good health and free of any disease or physical condition which might, in the investigator's opinion, expose the subject to an unacceptable risk by study participation.
Women of childbearing potential must have a negative urine pregnancy test and agree to use an effective, non-prohibited form of birth control for the duration of the study (abstinence, stabilized on oral contraceptives for at least two months, implant, injection, IUD, patch, NuvaRing, condom and spermicidal or diaphragm and spermicidal).

Exclusion Criteria:

Is nursing or planning a pregnancy during the study.
Has used topical antifungal or corticosteroid therapy or systemic antibacterial therapy within 30 days prior to the start of the study.
Has received systemic antifungal therapy within 12 weeks prior to the start of the study medication.
Has a history of diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications).
Has concurrent tinea infection (in the opinion of the investigator). However, concurrent onychomycosis is allowed.
Has any other skin disease which might interfere with the evaluation of tinea pedis.
Is currently enrolled in an investigational drug or device study.
Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study
Is unreliable, including subjects with a history of drug or alcohol abuse.
Has known hypersensitivity to any of the components of the study medications.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00768599

Locations

United States, California
Stacy Smith, MD
San Diego, California, United States, 92123
United States, Michigan
Daniel Stewart, DO
Clinton Township, Michigan, United States, 48038
United States, Minnesota
Steven Kempers, MD
Fridley, Minnesota, United States, 55432
United States, Tennessee
Michael Gold, MD
Nashville, Tennessee, United States, 37215
United States, Texas
Michael Jarratt, MD
Austin, Texas, United States, 78759
United States, Utah
Leonard Swinyer, MD
Salt Lake City, Utah, United States, 84124

Sponsors and Collaborators

Quinnova Pharmaceuticals, Inc.

More Information

Responsible Party:	Quinnova Pharmaceuticals ( David Miska, Ph.D., Senior Director, Clinical and Regulatory Affairs )
Study ID Numbers:	D79-2902-07
Study First Received:	October 7, 2008
Last Updated:	October 10, 2008
ClinicalTrials.gov Identifier:	NCT00768599
Health Authority:	United States: Food and Drug Administration

Keywords provided by Quinnova Pharmaceuticals, Inc.:

Econazole
Foam
Quinnova

Study placed in the following topic categories:

Pruritus
Skin Diseases
Clotrimazole
Miconazole
Tioconazole
Foot Diseases
Tinea Pedis

Mycoses
Signs and Symptoms
Skin Diseases, Infectious
Econazole
Tinea
Dermatomycoses

Additional relevant MeSH terms:

Anti-Infective Agents
Skin Manifestations
Foot Dermatoses
Therapeutic Uses

Antifungal Agents
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009